HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Feb. 20, 2019 (Pharmacist's Briefing) -- Long-term outcomes are more favorable for early intensive treatment (EIT) versus first-line moderate-efficacy disease-modifying therapy (DMT) in multiple sclerosis (MS), according to a study published online Feb. 18 in JAMA Neurology.
Katharine Harding, Ph.D., from Cardiff University in the United Kingdom, and colleagues examined long-term outcomes in a cohort study analyzing data for 592 patients with MS prescribed DMT. Patients were classified by first-line treatment strategy: high-efficacy (EIT) or moderate-efficacy DMT (escalation [ESC]).
The researchers found that compared with the ESC group, the EIT group had a lower mean five-year change in Expanded Disability Status Scale score (0.3 versus 1.2); after adjustment for relevant covariates, this result remained significant (β = −0.85; 95 percent confidence interval, −1.38 to −0.32; P = 0.002). The median time to sustained accumulation of disability (SAD) was 6.0 and 3.14 years for EIT and ESC, respectively (P = 0.05). The median time to SAD was 3.3 years for those within the ESC group who escalated to high-efficacy DMT as second-line treatment (compared with EIT, group log-rank test P = 0.08). Of those who escalated to high-efficacy DMT, 60 percent developed SAD while still receiving initial moderate-efficacy treatment before escalation.
"Our study undermines the prevalent belief that an escalation approach represents a lower-risk strategy to MS treatment and suggests that in the real world, an escalation approach to DMT may be inadequate to prevent unfavorable long-term outcomes," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.